Calibre Post Acute: Drug Review Failures - NM
Federal inspectors found the facility failed to ensure doctors provided required justification when rejecting consultant pharmacist recommendations during their November investigation.
The case involved a resident admitted in October 2024 with dementia, insomnia, and major depressive disorder. The patient had been taking escitalopram 20 mg daily since arriving at the facility on Sagecrest Avenue.
In July, the consulting pharmacist recommended the resident be evaluated for a dose decrease after nearly nine months on the same amount. The medication is an antidepressant used primarily to treat major depression and anxiety disorders.
The physician's response was brief. According to inspection records, the provider documented "resident with good response, maintain current dose" and "disagree with the pharmacist recommendation."
Nothing else.
Federal regulations require doctors to provide clinical rationale when declining pharmacist recommendations for dose reductions. The physician provided none.
The Director of Nursing confirmed during interviews that the resident had been taking the same escitalopram dose since admission. She acknowledged the pharmacist had recommended a gradual dose reduction in July and that the provider declined without documenting clinical reasoning.
The facility's Medical Director told inspectors that dose reductions for antidepressants should be attempted if residents aren't showing signs of depression. Providers were expected to document clinical rationale when refusing such recommendations, he confirmed.
The resident was also taking oxcarbazepine, an anticonvulsant medication. Initially prescribed in October 2024 for seizure control, it was discontinued in May, then restarted the same day specifically for depression treatment.
A third medication, trazodone, was prescribed for sleep assistance in November 2024, then reordered in June specifically for insomnia.
Inspectors found no documentation anywhere in the resident's medical record explaining why the escitalopram dose reduction shouldn't be conducted.
The deficiency puts residents at risk of receiving unnecessary medications that may cause drug interactions or adverse side effects, inspectors determined. When multiple psychiatric medications are prescribed together, the potential for harmful combinations increases.
Gradual dose reduction, known as GDR in medical terminology, is a standard practice for evaluating whether residents still need their current medication levels. The process involves slowly decreasing doses while monitoring for symptom return.
For antidepressants specifically, the approach helps determine if lower doses can maintain therapeutic benefit while reducing side effect risks. Common side effects of escitalopram include nausea, drowsiness, and sexual dysfunction.
The inspection occurred following a complaint and affected multiple residents. Inspectors reviewed three residents for depression-related medication management and found documentation failures in one case.
Federal guidelines require monthly drug regimen reviews by licensed pharmacists, including examination of medical charts and reporting of irregularities. When pharmacists identify potential medication problems, physicians must either implement recommendations or document medical reasons for declining.
The documentation requirement exists specifically to protect residents from prolonged exposure to unnecessary medications. Without clear rationale, inspectors cannot determine whether continued treatment serves the resident's best interests.
Calibre Post Acute operates as a skilled nursing facility providing post-acute rehabilitation services. The facility must submit a plan of correction addressing how it will ensure physicians document clinical reasoning when declining pharmacist recommendations.
The resident continues taking the same escitalopram dose that prompted the pharmacist's original reduction recommendation four months ago.
Full Inspection Report
The details above represent a summary of key findings. View the complete inspection report for Calibre Post Acute, LLC from 2025-11-18 including all violations, facility responses, and corrective action plans.
Additional Resources
Data source: Official federal inspection data from the Centers for Medicare & Medicaid Services (CMS).
Editorial process: AI-synthesized regulatory data, reviewed for accuracy by our editorial team.
Professional review: All content reviewed by Christopher F. Nesbitt, Sr., NH EMT & BU-trained Paralegal.
Last verified: June 20, 2026 · Our methodology
Calibre Post Acute, LLC in Las Cruces, NM was cited for violations during a health inspection on November 18, 2025.
The case involved a resident admitted in October 2024 with dementia, insomnia, and major depressive disorder.
Health inspections identify deficiencies that facilities must correct. Violations range from minor documentation issues to serious safety concerns. Review the full report below for specific details and facility response.